Translational relevance
Circulating microRNAs are emerging as promising biomarkers for various human diseases including colorectal cancer. To reduce colorectal cancer-related mortality, diagnosis of the disease at curable stages such as precancerous lesions and early cancers is highly important. Although many studies have suggested the potential utility of circulating microRNAs in colorectal cancer detection, their potential for detecting precancerous lesions remains poorly understood. In this study, we analyzed a large cohort of serum samples from patients with early colorectal neoplasms, in which the majority only had precancerous lesions, and demonstrated that expression levels of miR-21, miR-29a and miR-125b could discriminate patients from healthy controls. Our findings of serum microRNAs as diagnostic biomarkers of precancerous colorectal lesions provide rationale for the further development of these molecular signatures as screening biomarkers for this fatal malignancy.
Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in men and women, with more than 50,000 deaths annually in the United States (1). The 5-year survival for patients with localized disease is 89.8%, so CRC is a potentially curable disease if diagnosed early. However, only 39.6% of patients are diagnosed at this stage (2) . Moreover, since most CRCs develop through a stepwise adenoma-carcinoma sequence or the serrated pathway, most patients would be cured if the disease were detected and resected at a precancerous stage. Therefore, detection of early colorectal neoplasms (CRNs) -including precancerous lesions and early CRCs -is essential in reducing mortality associated with CRC.
Current guidelines recommend colonoscopy and fecal occult blood tests for CRC screening (3) (4) (5) . Although colonoscopy is regarded as the gold standard for detecting CRNs, this approach has several limitations. It is an invasive and expensive procedure, requires an unpleasant bowel preparation, its efficacy depends on the skill and experience of the endoscopist, and a significant percentage of adults prefer noninvasive options for CRC screening (4) . Fecal occult blood testing is a commonly used non-invasive test for CRC screening, and has demonstrated a reduction in CRC mortality by 33% to 15%, if used annually or semi-annually respectively (4, 6) .
However, fecal tests are not recommended for detecting precancerous lesions, due to the limited sensitivity and specificity, which is further compromised by inappropriate handling of specimens or poor adherence to recommended guidelines (4, 7 CRCs, this approach has important limitations; the detection of precancerous lesions was moderate, and the sensitivity for proximal lesions was inferior to that for distal lesions (8) . There is considerable room for improving the noninvasive approach to CRN screening.
MicroRNAs (miRNAs) are small non-coding RNA sequences of [19] [20] [21] [22] [23] [24] [25] nucleotides which function as post-transcriptional regulators of gene expression (9) , and dysregulation of miRNAs has been implicated in human cancers (10) . In colorectal carcinogenesis, it has been shown that many miRNAs are dysregulated during the progression from normal to precancerous and cancerous pathology (11) (12) (13) .
As some of these dysregulated miRNAs are secreted into blood, and circulating cell-free miRNAs can be detected in serum or plasma in highly stable form, circulating miRNAs have emerged as potential blood-based biomarkers for human cancer (9, 14, 15) . To date, several miRNAs have been reported as promising diagnostic biomarkers for CRC (16) (17) (18) (19) (20) (21) (22) (23) (24) , indicating the potential role of circulating miRNAs as minimally invasive biomarkers for CRC. Some evidence suggests that circulating miRNAs may be able to discriminate individuals with advanced adenomas -which represent a subset of precancerous lesions including large (≥10 mm) tubular adenomas (TA), adenoma with a villous component, and high-grade intraepithelial neoplasia (HGIN) -from healthy controls (17) (18) (19) (20) 23) . These results are important as they show the potential of circulating miRNAs for detecting individuals with precancerous CRNs, but their use in clinical medicine is limited due to the small number of studies, small sample sizes and lack of clinicopathological information on studied patients.
Consequently, systematic studies are required to further elucidate the utility of circulating miRNAs as biomarkers for early detection of CRNs.
Herein, we have analyzed a large cohort of serum specimens from patients 
Materials and Methods

Study subjects
Study subjects were prospectively enrolled at participating hospitals in Japan between information was obtained from medical charts and questionnaires filled out by the participants. Written informed consent was obtained from all subjects, and the study protocol was approved by the Institutional Review Board of participating institutions.
Study design
Schematic representation of this study is illustrated in Figure 1 . Our study consisted of three parts: a systematic literature review for candidate miRNA biomarker selection, a screening phase, and a validation phase. The screening phase included patients with 24 early CRN and 25 healthy subjects, and a validation phase included 136 patients with early CRN and 52 healthy subjects. In the screening phase, serum levels of 9 miRNAs (miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-24, miR-29a, miR-92a, and miR-125b) were investigated by quantitative real-time RT-PCR in sera from 24 early CRN patients and 25 healthy controls. In the validation phase, an independent cohort of 136 early CRN patients and 52 healthy controls were utilized to examine serum levels of miR-21, miR-29a and miR-125b.
RNA extraction
RNA was extracted from serum samples using miRNeasy Serum/Plasma Kits 
Power calculations and statistical analysis
Power calculations to determine the required sample sizes in the validation phase were performed by G*Power 3 (25) based on the data from the screening phase. To compare the serum miRNA levels between two groups, the Mann-Whitney U test was among three or more groups. Correlation between the size of the index lesion and the serum levels of miR-21, miR-29a and miR-125b were analyzed by the Spearman's rank correlation coefficient (ρ). All P-values were two-sided and a P-value of <0.05 was considered significant. Receiver operating characteristic (ROC) curves were generated and the area under the ROC curve (AUC) with 95% confidence intervals (CI) were computed to assess the discriminating performance of miR-21, miR-29a and miR-125b. All analyses were carried out using JMP ® 10 (SAS institute Inc., Cary, NC, USA) and graphs were generated using Graphpad Prism 5.00 for Windows (Graphpad software, San Diego, CA, USA) except for the ROC curves, which were analyzed using Medcalc Statistical Software version 12.7.7 (Medcalc Software bvba, Ostend, Belgium). 
Results
Candidate miRNA biomarker selection
Since one of the primary goals of our study was identification of diagnostic biomarkers for early CRNs, we first selected miRNAs that had been reported to be dysregulated in early CRN tissues (11, 13, (26) (27) (28) (29) (30) . We found 175 miRNAs that have been reported to be dysregulated in early steps during colorectal carcinogenesis. To narrow our candidate list exclusively to secretory miRNAs that may be detectable in blood, we next selected miRNAs dysregulated in serum or plasma from CRC and/or colorectal adenoma patients. (16) (17) (18) (19) (20) (21) (22) (23) (24) . We chose only miRNAs showing consistent dysregulation in tissues and serum or plasma among multiple studies, and identified 20 such miRNAs. We thereafter excluded 6 miRNAs that were discovered solely by Table S1 ). Five miRNAs (miR-409-3p, miR-424, miR-575, miR-601 and miR-760) were further excluded because serum expression levels of these miRNAs were too low to be accurate quantifed by real-time RT-PCR in our preliminary experiment (data not shown). As a result, 9 miRNAs (miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-24, miR-29a, miR-92 and miR-125b) were selected as candidate biomarkers for the early detection of CRNs.
The screening phase
In the screening phase, expression levels of the above-mentioned 9 miRNAs in serum samples from 24 early CRN patients and 25 healthy controls were examined. As shown in Figure 2 , serum levels of miR-21 (P=0.0007), miR-29a (P<0.0001) and miR-125b (P= 0.020) were significantly higher in early CRN patients than in healthy 
The validation phase
First, we performed power calculations by G*Power 3 (25) to determine the sample size required in the validation phase. Based on the miR-125b data in the screening phase, which showed the smallest effect size among the three candidate miRNAs, we estimated a minimal sample size of 122 early CRN patients and 30 healthy controls would be required to achieve 0.95 power.
Finally, we utilized serum samples from 136 early CRN patients and 52 healthy controls ( Table 1) to validate the discriminatory capability of miR-21, miR-29a and miR-125b. As shown in Figure 3A , serum levels of miR-21 (P<0.0001), miR-29a (P<0.0001) and miR-125b (P<0.0001) were significantly higher in early CRN patients than in healthy controls. As shown in Supplementary figure 1, increased levels of 3 miRNAs were significant even when we excluded 8 patients with CRCs and compared only patients with non-invasive CRNs to healthy subjects. When we divided CRN patients into either having ANs or not (non-ANs), expression levels of miR-21 and miR-29a were significantly elevated in AN patients compared to non-AN patients and healthy controls, whereas miR-125b levels increased in both non-AN and AN patients compared to healthy controls ( Figure 3B) . Serum levels of miR-21 and miR-29a significantly correlated with the size of the index lesions, while miR-125b showed no correlation ( Figure 3C ).
Next, we generated ROC curves to evaluate the performance of the three 
Serum miR-21, miR-29a and miR-125b levels and characteristics of early CRNs
Given that serum miR-125b levels were significantly elevated in non-ANs, which consisted of TAs and SPs less than 10 mm in size, we determined whether the levels of miRNAs were elevated in patients with even smaller CRNs. We calculated the total diameters of all CRNs detected in an individual, and found that 11 of 136 patients had CRNs with total diameter of 5 mm or less. Serum expression levels of miR-29a and miR-125b were significantly higher in patients who only had small CRNs (total diameter of CRNs ≤5 mm) than in healthy controls. (P=0.022 and P=0.001, respectively, Figure 5A) We analyzed serum miRNA expression levels according to histological subtypes of CRNs. Compared to healthy controls, patients with TAs and HGINs showed significantly higher serum levels of all three miRNAs, while patients with TVAs had significantly elevated levels of serum miR-29a and miR-125b. (Figure 5B Table S2 , there were no significant association between serum levels of the three miRNAs and age, gender, the presence of concurrent disorders, location or morphology of the CRNs.
Discussion
In this study, we analyzed a cohort of 237 serum samples in independent screening and validation sets, and found that the levels of miR-21, miR-29a and miR125b in serum could discriminate patients with early CRNs from healthy controls. To our knowledge, this is the first study to systematically investigate circulating miRNA biomarkers focused on the identification of precancerous CRNs -the optimal target lesion for a CRC screening strategy.
Although genome-wide miRNA profiling approaches such as microarrays have been successfully utilized for the discovery of novel miRNA biomarkers for the early detection of CRNs, the outcomes have been largely inadequate for clinical decision making due to the limited number of studies and small numbers of samples analyzed. In fact, a few recent studies have found multiple miRNAs that could discriminate precancerous adenoma patients from healthy controls by using microarray; however, none of these studies identified common overlapping miRNA biomarkers, raising concerns about the discovery and validation methodologies used in these reports (18) (19) (20) . In the current study, we started with a systematic literature review rather than genome-wide approaches for the selection of candidate miRNAs.
This enabled us to choose miRNAs that have been found by independent researchers using different patient cohorts. Since reproducibility is one of the most critical components in the discovery of clinically relevant biomarkers, we believe our strategy 
has an advantage in finding more generally applicable markers.
The most remarkable findings of our study were that serum miR-21, miR-29a and miR-125b could discriminate early CRN patients from healthy controls. By performing a power calculation, we were able to analyze a sufficient number of subjects to reach this conclusion with appropriate statistical power. MiR-125b showed the best performance among the three miRNAs to discriminate early CRN patients from healthy subjects. Serum miR-125b levels were elevated in non-AN patients (i.e.
TAs and/or SPs smaller than 10 mm) compared to healthy controls, and no significant increase was observed in AN patients. Surprisingly, elevated levels of miR-125b were seen even in patients whose total diameters of CRNs were 5 mm or less. Thus, the increase in serum miR-125b levels most likely reflects an earlier step during colorectal carcinogenesis. In contrast, serum levels of miR-21 and miR-29a were elevated significantly in patients with ANs compared to healthy controls and non-AN patients.
Considering that the most relevant lesions in CRC screening would be precancerous lesions which possess higher risks of progressing to cancers, miR-21 and miR-29a might be better biomarkers to detect more risky lesions such as ANs. collected by the subjects themselves, quality control may be easier using blood rather than stool. In addition, the use of blood samples may lead to better compliance than expecting patients to properly collect and ship stool.
There are some potential limitations of our study. First, the healthy volunteers in our study were younger than CRN patients. To minimize the bias caused by the age differences between the two groups, we assigned healthy volunteers of a similar age range with subjects undertaking CRC screening in the general population to the validation set. Second, hemolysis is known to affect levels of circulating biomarker miRNAs (32). As we saw some hemolyzed samples in our study subjects, hemolysis might confound our results. Impacts of confounding factors including hemolysis should be evaluated in the future study. Third, our study lacked an independent, large validation cohort, which must be considered in future investigations to further appreciate the clinical significance of the findings reported in this study.
In conclusion, we conducted a systematic investigation to identify circulating miRNA biomarkers for CRC screening, and found that serum miR-21, miR-29a and miR-125b levels could discriminate early CRN patients from healthy controls. Our data highlight the capability of serum miRNAs to detect precancerous CRNs, suggesting the potential clinical use of these molecular signatures for noninvasive screening of patients for CRC. Levels of miRNAs were compared among HCs, patients with small CRNs (total
